Apyx Medical Corporation (APYX) News
Filter APYX News Items
APYX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APYX News Highlights
- For APYX, its 30 day story count is now at 5.
- Over the past 22 days, the trend for APYX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about APYX are LI, UL and DRUG.
Latest APYX News From Around the Web
Below are the latest news stories about APYX MEDICAL CORP that investors may wish to consider to help them evaluate APYX as an investment opportunity.
Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following LiposuctionCLEARWATER, Fla., February 01, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced it has submitted a 510(k) premarket notification ("510(k) submission") for the Renuvion APR Handpiece to the U.S. Food and Drug Administration ("FDA"), supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion’s indications for use |
Recent uptick might appease Apyx Medical Corporation (NASDAQ:APYX) institutional owners after losing 72% over the past yearIf you want to know who really controls Apyx Medical Corporation ( NASDAQ:APYX ), then you'll have to look at the... |
APYX MEDICAL CORPORATION LAUNCHES NEW 'APYX ONE CONSOLE' FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATESApyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of its latest-generation Renuvion generator, the Apyx One Console, in the United States. |
Apyx Medical narrows FY revenue guidance, guides Q4 and FY revenue outlook below estimates
|
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue ResultsCLEARWATER, Fla., January 10, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022. |
APYX® MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION®Apyx® Medical Corporation (NASDAQ: APYX), the manufacturer of Renuvion®, a proprietary helium plasma and radiofrequency technology, today announces the launch of its first-ever direct-to-consumer brand campaign. Entitled #ThisIsMe, the campaign is aimed at U.S. consumers who are interested in a minimally invasive procedure with the Renuvion technology. |
Apyx Medical Corporation to Participate in the Piper Sandler 34th Annual Healthcare ConferenceCLEARWATER, Fla., November 22, 2022--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Piper Sandler 34th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY. Management will participate in fireside chat on Wednesday, November 30 at 11:00 a.m. ET. |
Apyx Medical Third Quarter 2022 Earnings: Misses ExpectationsApyx Medical ( NASDAQ:APYX ) Third Quarter 2022 Results Key Financial Results Revenue: US$9.11m (down 23% from 3Q... |
Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Apyx Medical (APYX) and Phathom Pharmaceuticals (PHAT)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB – Research Report), Apyx Medical (APYX – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report). Biogen (BIIB) In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen, with a price target of $325.00. The company's shares closed last Thursday at $289.77, close to its 52-week high of $292.45. According to TipRanks. |
Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue EstimatesApyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |